Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database

Respir Med. 1998 Nov;92(11):1302-4. doi: 10.1016/s0954-6111(98)90232-3.

Authors

D B Price¹, K Cargill, S Wolfe, H Darby

Affiliation

¹ GlaxoWellcome U.K., Uxbridge, Middlesex, U.K.

PMID: 9926144
DOI: 10.1016/s0954-6111(98)90232-3

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Adrenergic beta-Agonists / economics*
Adrenergic beta-Agonists / therapeutic use*
Adult
Albuterol / analogs & derivatives*
Albuterol / economics
Albuterol / therapeutic use
Asthma / drug therapy*
Case-Control Studies
Cost-Benefit Analysis
Databases, Factual
Drug Costs
Drug Therapy, Combination
Family Practice
Female
Humans
Male
Retrospective Studies
Salmeterol Xinafoate
Statistics, Nonparametric
Treatment Outcome

Substances

Adrenal Cortex Hormones
Adrenergic beta-Agonists
Salmeterol Xinafoate
Albuterol